Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.37 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24752804 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2EPHX1 | |
| SCHEMBL13661298 | 0.88 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL1086226 | 0.87 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL154164 | 0.85 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL16130103 | 0.84 | USP2 (0.45) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| Hydrochloric Acid SCHEMBL17714540 | 0.84 | USP2 (0.47) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2349423 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2945193 | 0.83 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL849402 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL | |
| SCHEMBL2525447 | 0.82 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | C4 THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691972-B2 | Compounds for targeted degradation of BRD9 | BRD9, BRD1, BRWD1 | USP2 308/4885SMN1; SMN2 725/4885HPGD 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.